



G202/01088



INVESTOR IN PEOPLE

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 05 JUN 2002


WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Stephen Hordley

Dated 26 March 2002



Patents Act 1977
(Rule 16)



13MAR01 E613033-1 D01030
P01/7700 0.00-0106046.6
1/77

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1. Your Reference	AJT/PG4383		
2. Patent application number (The Patent office will fill in this part)	0106046.6		12 MAR 2001
3. Full name, address and postcode of the or of each applicant (underline all surnames)	GLAXO GROUP LIMITED GLAXO WELLCOME HOUSE BERKELEY AVENUE GREENFORD MIDDLESEX UB6 0NN GB		
Patents ADP number (if you know it)	473587003		
If the applicant is a corporate body, give the country/state of its corporation	GB		
4 Title of the invention	CANISTER		
5 Name of your agent (if you know one)	ANDREW J. TEUTEN (SEE CONTINUATION SHEET)		
"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)	GLAXOSMITHKLINE GLAXO WELLCOME HOUSE, BERKELEY AVENUE GREENFORD, MIDDLESEX UB6 0NN, GB		
Patents ADP number (if you know it)	807 2555 002		
6. If you are declaring priority from one or more earlier patent applications, give the country and date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of Filing (day / month / year)
7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application		Date of filing (day / month / year)
8. Is a statement of inventorship and of right to grant a patent required in support of this request? (Answer yes if: a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is not named as an applicant, or c) any named applicant is a corporate body.	YES		

See note (d))

Patents Form 1/77

Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form 1

Description 19

Claim(s) 2

Abstract 0

Drawing(s) 0



10. If you are also filing any of the following, state how many against each item

Priority Documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patent Form 9/77)

Request for substantive examination (Patent Form 10/77)

Any other documents (please specify)

11. I/We request the grant of a patent on the basis of this application

Signature Andrew J. Teuten

Date 12th March 2001

AGENT FOR THE APPLICANTS

12. Name and daytime telephone number of person to contact in the United Kingdom
Debbie Hallissey
020 8966 8055

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication of communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the patent Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been received

a) Notes

If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.

b) Write your answers in capital letters using black ink or you may type them.

c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form

If you have answered "Yes" Patents Form 7/77 will need to be filed.

d) Once you have filled in the form you must remember to sign and date it.

e) For details of the fee and ways to pay please contact the Patent Office.

Additional Agents
(See Page 1 No. 5)

NAME(S)

Michael ATKINSON
Karen CRAWLEY
Peter I. DOLTON
Hugh B. DAWSON
Wendy Anne FILLER
Ruth Elizabeth HACKETT
Siân Catherine HOCKLEY
Stephanie Anne LEAROYD
Helen Kaye QUILLIN
Michael A REED
Marion REES
Michael John STOTT
Peter Graham STUART
Andrew J. TEUTEN
Rachel M. THORNLEY
Janis Florence VOLCKMAN

ADDRESS

GlaxoSmithKline
Glaxo Wellcome House
Berkeley Avenue
Greenford
Middlesex
UB6 ONN
Great Britain



Canister

This invention relates to an improved canister for use in metered dose inhalers (MDI's), especially to a canister which may contain and dispense pressurised formulations of pharmaceutical substances in hydrofluoroalkane propellants.

Metered dose inhalers are a widely used system for delivery of pharmaceutical substances to the lung and upper airways. As such they have become established as a delivery system for pharmaceuticals for the treatment of respiratory disorders such as asthma and chronic obstructive pulmonary disease.

Metered dose inhalers typically comprise a canister fitted with a valve such as a metering valve which is fitted into a suitable channelling device to permit inhalation. Suitable channelling devices comprise, for example a valve actuator and a cylindrical or cone-like passage through which medicament may be delivered from the filled canister via the metering valve to the nose or mouth of a patient e.g. a mouthpiece actuator. In a typical arrangement the valve stem is seated in a nozzle block which has an orifice leading to an expansion chamber; the expansion chamber has an exit orifice which extends into the mouthpiece.

Metered dose inhalers operate by dispensing a metered volume of formulation by means of the metering valve from a bulk supply of formulation contained within the canister which generally consists of a suspension or solution of a substance in a liquefied propellant gas. In the past the preferred propellant gases were CFC's such as P11, P12 and 114. Following the discovery that CFC's are capable of causing depletion of atmospheric zone, however, alternative propellants have been developed. The currently most favoured alternative propellants are hydrofluoroalkanes, especially 1,1,1,2-tetrafluoroethane (HFA134a) and 1,1,1,2,3,3,3-heptafluoro-n-propane (HFA227).

The medical community has been engaged for many years now in the process of formulating old and new medicines in the alternative propellants. It is now generally recognised that because of certain chemical and physical differences between the old and new propellants certain other modifications to the MDI system have been

considered advisable. For example, the surfactants previously commonly used as dispersing agents in suspension based CFC formulations are not effective since they are inadequately soluble in hydrofluoroalkanes without the addition of a co-solvent to the formulation. Efforts are being made to develop novel surfactants which are soluble
5 in hydrofluoroalkanes (see e.g. WO96/09816 of Glaxo Inc). A system has also been developed in which the surfactant is omitted altogether (see e.g. WO93/11743 of Glaxo Group).

Certain suspension formulations of pharmaceutical products in hydrofluoroalkanes have
10 demonstrated a tendency to suffer drug losses due to deposition of drug substances on the canister walls. Also the possibility of interaction between the formulation and the canister walls cannot always be excluded. For this reason canister coatings have been developed e.g. coatings of a fluorocarbon polymer optionally in combination with a non-fluorocarbon polymer (see e.g. WO96/32151 of Glaxo Wellcome Inc). Coatings of
15 epoxy-phenol resins are described in WO00/30608 (Chiesi). WO00/78286 (3M) describes coatings including a thin film of glass. Processes employed in order to apply and cure such coatings which involve use of elevated temperature can cause distortion of conventional aluminium canisters. Accordingly aluminium canisters have been developed with certain strengthening features such as thicker walls and ellipsoidal base,
20 however these are relatively expensive to manufacture.

Stainless steel is known as an alternative strong material for manufacture of canisters however lengths have to be taken to avoid corrosion e.g. as described in WO00/73170 (Boehringer Ingelheim) and use of special alloys is also expensive.
25

We have now invented a canister suitable for use in metered dose inhalers which eliminates or substantially mitigates a number of the disadvantages of prior art canisters.

30 Thus according to the invention we provide a canister suitable for use in metered dose inhalers and fitted with a metering valve characterised in that its walls are formed of a laminate comprising a first layer which is composed of a metal and a second layer which is composed of a strengthening material.

Such canisters are advantageous in that the laminate is capable of providing equivalent or greater strength than thicker walled aluminium cans at more reasonable cost. Furthermore problems associated with possible interaction between the metal and the contents of the can or the atmosphere may be avoided.

5

Laminate when used in this specification will be understood to mean a material comprising two or more layers each of which make a contribution to the structural integrity of the canister when attached together.

10

Metals suitable for use according to the invention include pure metal or metal alloys which have optionally been pre-treated or processed e.g. galvanised, annealed, plated or coated to improve their properties. Preferably the metal is selected from the list consisting of aluminium, steel, copper, brass, tin and chromium, especially aluminium or steel, particularly aluminium.

15

The strengthening material will be a material that when used in conjunction with the metal layer forms a product of greater strength than a similar conventional product not prepared from a laminated material. The strengthening material may have an inherent ability to resist stress or the ability may be realised when used in conjunction with the metal layer.

20

One or more of the following materials may be used as a strengthening layer:

- i) a metal or an alloy e.g. aluminium, steel, iron, copper, tin, brass or chromium; or
- ii) a metal oxide e.g. chromium oxide (which has good abrasive resistance and additionally is resistant to corrosion), alumina or tantalum oxide; or
- iii) a plastics material such as: polyester, epoxy resin, phenolic resin, phenoxy resin, epoxy-phenol resin, polypropylene, acrylonitrile-styrene copolymer, acrylonitrile-styrene-butadiene copolymer, high-impact polystyrene, nylon, polyacetal, polycarbonate, polytetrafluoroethylene, polyethylene terephthalate, an unsaturated nitril resin, polyvinylchlorides, polyurethanes or polyphenylene oxides; optionally reinforced with a suitable filler material e.g. carbon fibres, filaments of glass, metal, boron, aluminium silicate, calcium carbonate, talc or barium sulphate; or
- iv) a ceramic e.g., silicon oxide; or

25

30

v) a carbide (e.g. a carbide of a metal such as iron, calcium, tungsten or silicon or boron).

5 The strengthening layer may be made from the same material as the metal (e.g. the laminate may be formed from two or more aluminium layers), although preferably the strengthening layer is usually selected from a different material to that of the first metal layer.

The laminate may optionally include one or more other layers such as:

- 10 i) a bonding layer e.g. a layer of adhesive such as an epoxy resin, thermoset adhesive or cyanoacrylate;
- ii) a layer e.g. of a metal oxide which may be used to effect or improve adhesion between other layers such as between the metal layer and the strengthening layer
- 15 iii) a coating layer e.g. applied to part or all of the internal and/or external surface of the laminate so as to serve one or more of the following purposes:
- a) reduction of interaction of a layer of laminate with the atmosphere (e.g. in the case of the coating layer applied to the external surface);
- b) reduction of interaction of a layer of laminate with the contents of the canister (e.g. in the case of the coating layer applied to the internal surface);
- 20 c) reduction of deposition of particulate matter from the contents of the canister onto a layer of laminate (e.g. in the case of the coating layer applied to the internal surface).

25 The above optional layers may perform more than one function, for example, adhesives may also distribute stress at the bond point and/or resist moisture and or corrosion. Similarly the oxide layer may be resistant to corrosion.

30 A first particular embodiment is provided wherein the second layer of strengthening material is a reinforced plastic such as polyester, polypropylene, acetonitrile-styrene copolymer, high-impact styrene, nylon or polyacetal and the first metal layer is composed of a material selected from aluminium or steel and characterised in that the first metal layer forms the internal surface of the canister and is optionally coated with one or more coating layers. An adhesive layer may optionally be used between the reinforced plastic layer and the first metal layer.

A second particular embodiment is provided wherein the second layer of strengthening material is a reinforced plastic such as polyester, polypropylene, acetonitrile-styrene copolymer, high-impact styrene, nylon or polyacetal and is optionally coated with one or more coating layers and the first metal layer is composed of a material selected from aluminium or steel and characterised in that the first metal layer forms the external surface of the canister and is optionally coated with one or more coating layers. An adhesive layer may optionally be used between the reinforced plastic layer and the first metal layer.

According to a third particular embodiment of the invention we provide a canister suitable for use in metered dose inhalers characterised in that its walls are formed of a laminate wherein the laminate comprises a first metal layer of material forming the external surface of the canister selected from the list of metals consisting of: aluminium, brass, copper, chromium, iron, tin and steel, optionally coated with one or more coating layers, and a second layer of material selected from the list of strengthening materials consisting of aluminium, brass, copper, chromium, chromium oxide, iron, tin and steel, optionally coated with one or more coating layers.

According to a fourth particular embodiment of the invention we provide a canister suitable for use in metered dose inhalers characterised in that its walls are formed of a laminate wherein the laminate comprises a first metal layer of material forming the internal surface of the canister selected from the list of metals consisting of: aluminium, brass, copper, chromium, iron, tin and steel, optionally coated with one or more coating layer, and a second layer of material selected from the list of strengthening materials consisting of aluminium, brass, copper, chromium, chromium oxide, iron, tin and steel, optionally coated with one or more coating layers.

The laminate may comprise further layers e.g. where the second layer is chromium a layer of chromium oxide may be present between the first and second layer and optionally an adhesive layer may be present.

Preferably the first metal layer is composed of stainless steel, aluminium or an alloy thereof, most preferably aluminium or stainless steel, especially aluminium.

Preferably the second layer of strengthening material is steel.

Thus in one embodiment of the invention the laminate is a laminate comprising one layer of steel and one layer of aluminium, optionally coated with one or more coating layers.

In a particularly preferred embodiment of the invention the wall of the canister is formed from a laminate comprising a layer of steel sandwiched between two layers of aluminium (i.e. is a laminate of one layer of steel and two layers of aluminium). Optionally the internal and/or external aluminium walls are provided with one or more coating layers. Preferably the internal wall of the canister will be coated with e.g. a fluorocarbon polymer coat such as PTFE or FEP; or a mixture of a fluorocarbon polymer with a non-fluorocarbon polymer such as PTFE or FEP and polyethersulphone; or an epoxy-phenol resin.

The steel for use according to the invention will generally consist of a ferrous alloy with greater than 50% iron and one or more of the following 0.1 to 10 wt% carbon (C), 0 to 10 wt% manganese (Mn), 0 to 10 wt% copper (Cu), 0 to 10 wt% silicon (Si), 0 to 50 wt% nickel (Ni), 0 to 10 wt% vanadium (V), 0 to 10 wt% niobium (Nb), 0 to 10 wt% aluminium (Al), 0 to 10 wt% molybdenum (Mo), 0 to 50 wt% chromium (Cr), 0 to 5 wt% phosphorus (P), 0 to 5 wt% sulphur (S), 0 to 30 wt% tungsten (W), 0 to 20 wt% cobalt (Co), 0 to 10 wt% columbium (Cb), 0 to 10 wt% oxygen (O), 0 to 10 wt% nitrogen (N) which may desirably be employed to improve the properties of the steel.

Stainless steel is a ferrous alloy as defined above which contains at least 12% chromium.

Where the steel is sandwiched between two layers of metals, preferably the steel used will be mild steel which is a ferrous alloy as defined above containing up to 2% carbon.

The total thickness of the laminate for the finished product is preferably in the range 0.2-2.0mm. When the laminate is a laminate of one layer of steel and one layer of aluminium or stainless steel the thickness of the layer is preferably in the range 0.1-1.0mm. When the laminate is a laminate of one layer of steel and two layers of

aluminium (or one layer of aluminium and one layer of stainless steel) the thickness of the sheets is preferably in the range 0.1-1.0mm. The thickness of the laminate may be reduced slightly with respect to the starting material when it is drawn into a canister.

5 As mentioned above, laminates may be prepared using an adhesive e.g. an epoxy resin with a molecular weight in the range 5000 to 30,000 (for further details see EP 0612 608). The adhesive will usually require curing e.g. by heating. Pressure sensitive adhesives (PSA) may also be used as an agent to bond the component layer together. The PSA may be activated by heating after assembly of the laminate and processing
10 using pressure lamination rollers (for further details please see USP 3970 496). This method is especially suitable when the laminate is composed of at least two layers which are a metal e.g. wherein the lamina comprises a layer of aluminium or stainless steel and a layer of steel or a sandwich as described above.

15 Alternative methods of preparing laminates include: surface activation of some or all the component lamina e.g. by using materials which when subjected to a mechanical force, such as pressure rollers with raised portions, some molecules/atoms of the two materials migrate and bind the said materials together, alternatively the migration of some molecules/atoms of the two material may be promoted by heating; electro
20 deposition e.g. electroplating with tin (for future details please see USP 5 298 149); or vapour deposition.

Canisters may be prepared from laminates by hot and/or cold drawing, extrusion or moulding. For further information on these processes please see Materials Science and
25 Engineering - an introduction by William D. Callister, Jr. (2nd edition), published by Wiley.

As mentioned above, canisters may be coated on their internal surface with a polymer e.g. a fluorocarbon polymer optionally in combination with a non-fluorocarbon polymer
30 as described in WO 96/32151.

Suitable fluoropolymers include polytetrafluoroethylene (PTFE), ethylenetetrafluoroethylene (ETFE), polyvinylidene fluoride (PVDF), perfluoroalkoxyalkane (PFA), polyvinyl fluoride (PVF), polychlorotrifluoroethylene

(PCTFE) and fluorinated ethylenepropylene (FEP). Fluorocarbon polymers are marketed under trademarks such as Teflon®, Tefzel®, Halar® and Hostaflon®, Polyflon® and Neoflon®. Grades of polymer include FEP DuPont 856-200, PFA DuPont 857-200, PTFE-PES DuPont 3200-100, PTFE-FEP-polyamideimide DuPont 856P23485, FEP powder DuPont 532, and PFA Hoechst 6900n.

Fluorinated polymers which have a relatively high ratio of fluorine to carbon such as perfluorocarbon polymers e.g. PTFE, PFA and FEP are preferred.

- 10 Suitable copolymers comprise from 1 to 99%, preferably from 5 to 95% by weight of fluorinated polymer. Suitable copolymers include copolymers of tetrafluoroethylene (TFE) with PFA, TFE with hexafluoropropylene (HFP) (available as FEP 6107 and FEP 100 from DYNEON), VDF with HFP (commercially available as Viton A), TFE with perfluoro(propyl vinyl ether) (available as PFA 6515N from DYNEON), a blend of TFE, 15 hexafluoropropylene and vinylidene fluoride (available commercially as THV 200G from DYNEON), HOSTAFORM X329™ (Hoechst) which is a 5% PTFE/Acetal blend, HOSTAFORM C9021TF which is a 20% PTFE/Acetal blend, PTFE/PBT blends (for example, LNP WL4040), and PTFE/PBT/silicone blends (for example, LNP WL4540).
- 20 The fluorinated polymer may be blended with non-fluorinated polymers such as polyamides, polyimides, polyamideimides, polyethersulphones, polyphenylene sulphides and amine-formaldehyde thermosetting resins. These added polymers improve adhesion to the canister walls, especially in the case of canisters lined with aluminium. Preferred polymer blends include PTFE/FEP/polyamideimide, 25 PTFE/polyethersulphone and FEP/benzoguanamine.

The preferred polymer is a blend of polyethersulphone (PES) and polytetrafluoroethylene (PTFE). Another preferred polymer for coating is pure FEP (fluorinated ethylene propylene). Another preferred polymer for coating is pure PFA.

30 Canisters may be coated by the means known in the art for metal coating. For example, a metal such as aluminium or stainless steel may be pre-coated as a coil and cured before being stamped or drawn out into the can shape. Alternatively, pre-formed


canisters may be sprayed inside with formulations of the coating polymer and then cured. The preformed canisters may also be dipped in the polymer coating formulation and cured, thus becoming coated on the inside and out. The polymer may also be formed in situ at the can walls using plasma polymerisation of the fluorocarbon monomers. The appropriate curing temperature is dependent on the polymer chosen for the coating and the coating method employed. However for coil coating and spray coating temperatures in excess of the melting point of the polymer are typically required, for example, about 50°C above the melting point, for up to 20 minutes. For the named preferred and particularly preferred polymers, curing temperatures in the range of around 300-400 °C e.g. around 350-380 °C are suitable.

Alternative coatings include: epoxy resin, phenolic resin, phenoxy resin, epoxy-phenol resin, epoxy-phenol-novolac and epoxy-cresol-novolac see WO00/30608.

Other suitable coatings comprise linear non-cross-linked fluorinated polymers. In one aspect, the coating compound comprises a functional grouping which is capable of anchoring the compound to the surface thereof. As a first example, the compound may be an organo-phosphate such as a phosphate based perfluoroether derivative.

Typically, the compound is a phosphoric ester.

In one first such embodiment, the interfacial surface has a compound disposed thereon having the general formula (I):




wherein R^1 comprises a fluoro-alkyl functional group;

x and y are such that the molecular weight of the compound is in the range 350-1000; and

R^2 comprises a phosphoric ester functional group.

In a second such embodiment, the interfacial surface has a compound disposed thereon having the general formula (II):



wherein R^3 comprises $-(OCH_2-CH_2)_z-OPO(OH)_2$;

5 x, y and z are such that the molecular weight of the compound is in the range 900-2100;
and v and w independently represent 1 or 2.

In one preferred embodiment, v and w are both 1. In a second preferred embodiment v and w are both 2.

10 Alternatively in a second embodiment the compounds may be an organo-silane derivative such as a silane derivative of perfluoropolyoxyalkane, e.g. a silane derivative of perfluoropolyoxyalkane having a molecular weight in the range 1600-1750. Examples include perfluoropolyoxyalkanes having functional groups of the type –
15 $CONR^4R^5$ wherein R^4 and R^5 may be independently selected from hydrogen, or a silyl ether (e.g. $SiR_t(OR)_{3-t}$) wherein R =hydrogen or C_{1-8} alkyl and t=0 to 2) as described in USP 4 746 550 which is incorporated herein by reference.

20 The synthesis of compounds of formula (I) and (II) may readily be determined by reference to EP 687 533 which describes similar compounds. EP 338 531 also provides information on the preparation of compounds of this type. Methods of preparing organo-silane polymeric compounds of the type described above may readily be determined by reference to USP 4 746 550.

25 Whilst not wishing to be bound by any theory, it is believed that the phosphate or silane moiety of the compounds of formula as described above reacts with the surface of the component to anchor the compound to the surface. Thus, when in use, the per-fluorinated end of the compound is presented to the pharmaceutical formulation and so provides a highly fluorinated surface.

30 Other suitable coatings include siloxanes such as dimethyl siloxane which in one aspect, may be applied by plasma polymerisation processes.

35 One suitable means of applying a fluorine-containing coating is by plasma coating, for example, by a CF_4 or fluorine ion plasma coating technique. The plasma coating may consist of a fluorinated polymer laid down on the surface of the component by

polymerisation or by modification of a hydrocarbon-containing pre-coating on the surface by interchange of hydrogen ions in the material with fluorine ions. The coating process typically takes place in a vacuum at ambient temperature. The components to be coated are placed inside a chamber which is evacuated. The fluorine monomer or fluorine source is introduced into the chamber at a controlled rate. The plasma is ignited within the chamber and maintained for a given time at a chosen power setting. For plasma polymerization typically temperatures in the range of about 20°C to about 100°C may be employed. At the end of the treatment the plasma is extinguished, the chamber flushed and the products retrieved. In the polymerisation process, a thin layer of plasma polymer will be bonded to the surface.

In one embodiment the internal wall of the canister may comprise a coating layer of high-nitril resin which is a co-polymer comprising an unsaturated nitril compound e.g. acrylonitrile or methacrylonitrile and an unsaturated copolymer e.g. an unsaturated aromatic compound, a diene compound an unsaturated ether compound or an unsaturated ester such as styrene, α -methylstyrene, butadiene, isoprene, methylacrylate, ethylacrylate, methylmethacrylate and ethylmethacrylate, wherein said co-polymer contains greater than 50 percent by weight of the unsaturated nitril unit. The nitril resin layer may be manufactured by methods such as multilayer blow moulding, multilayer injection-blow moulding and multilayer injection moulding. Optionally an adhesive layer may be used between the nitril resin layer and the metal layer. The nitril resin layer has the advantage of being resistant to chemical attack and strong.

An alternative coating is a thin layer of glass which may be deposited by gas vapour deposition on the internal wall of the canister.

The coating thickness will typically be in the range 0.1 micron to 1 mm, e.g. 1-100 microns especially 1 to 25 microns.

Coatings may be applied in one or more coats.

In use, the canister will be fitted with a valve e.g. a metering valve. The metering valve is designed to deliver a metered amount of the formulation per actuation and

incorporate a gasket to prevent leakage of propellant through the valve. Suitable valves are commercially available from manufacturers well known in the aerosol industry, for example, from Valois, France (eg. DF10, DF30, DF60), Bepak plc, UK (e.g. BK300, BK356, BK357) and 3M-Neotechnic Ltd, UK (eg. Spraymiser™). The DF31 valve of
5 Valois, France is also suitable.

Valve metering volumes of 25 μ l, 50 μ l, 63 μ l or 100 μ l are typical.

10 Other valve systems include, but are not limited to, wedge gate valve systems, double-disc gate valve systems, globe and angle valve systems, swing check valve systems, end cock valve systems, and other like valve systems.

15 Valve materials, especially the metering chamber, will preferably be manufactured of a material which is inert to and resists distortion by contents of the formulation, especially when the contents include ethanol. Particularly suitable materials for use in manufacture of the metering chamber include polyesters e.g. polybutyleneterephthalate (PBT) and acetals, especially PBT.

20 Materials for use in the manufacture of the metering chamber and/or the valve stem may desirably be fluorinated, partially fluorinated or impregnated with fluorine containing substances in order to resist drug deposition.

25 Valve seals, especially the gasket seal, and also the seals around the metering chamber, will preferably be manufactured of a material which is inert to and resists extraction into the contents of the formulation, especially when the contents include ethanol.

30 Gaskets may comprise any suitable elastomeric material such as for example low density polyethylene, chlorobutyl, black and white butadiene-acrylonitrile rubbers, butyl rubber, neoprene, EPDM (a polymer of ethylenepropylenediene monomer) (eg as described in WO95/02651) and TPE (thermoplastic elastomer; eg as described in WO92/11190).

The elastomeric material may either comprise a thermoplastic elastomer (TPE) or a thermoset elastomer which may optionally be cross-linked.

Typically, the sealing ring, which seals the valve to the can, and/or second sealing ring
5 comprise an elastomeric material. The ring is typically resiliently deformable.

The sealing ring may be formed by cutting a ring from a sheet of suitable material. Alternatively, the sealing ring may be formed by a moulding process such as an injection moulding, a compression moulding or a transfer moulding process.

10 The sealing ring may also comprise a thermoplastic elastomer blend or alloy in which an elastomeric material is dispersed in a thermoplastic matrix. The elastomers may optionally additionally contain conventional polymer additives such as processing aids, colorants, tackifiers, lubricants, silica, talc, or processing oils such as mineral oil in
15 suitable amounts.

Suitable thermoset rubbers include butyl rubbers, chloro-butyl rubbers, bromo-butyl rubbers, nitrile rubbers, silicone rubbers, fluorosilicone rubbers, fluorocarbon rubbers, polysulphide rubbers, polypropylene oxide rubbers, isoprene rubbers, isoprene-
20 isobutene rubbers, isobutylene rubbers or neoprene (polychloroprene) rubbers.

Suitable thermoplastic elastomers comprise a copolymer of about 80 to about 95 mole percent ethylene and a total of about 5 to about 20 mole percent of one or more comonomers selected from the group consisting of 1-butene, 1-hexene, and 1-octene as
25 known in the art. Two or more such copolymers may be blended together to form a thermoplastic polymer blend.

Another suitable class of thermoplastic elastomers are the styrene-ethylene/ butylene-styrene block copolymers. These copolymers may additionally comprise a polyolefin (e.g. polypropylene) and a siloxane.
30

Thermoplastic elastomeric material may also be selected from one or more of the following: polyester rubbers, polyurethane rubbers, ethylene vinyl acetate rubber,

styrene butadiene rubber, copolyether ester TPE, olefinic TPE, polyester amide TPE and polyether amide TPE.

5 Other suitable elastomers include ethylene propylene diene rubber (EPDM). The EPDM may be present on its own or present as part of a thermoplastic elastomer blend or alloy, e.g. in the form of particles substantially uniformly dispersed in a continuous thermoplastic matrix (e.g. polypropylene or polyethylene). Commercially available thermoplastic elastomer blend and alloys include the SANTOPRENE™ elastomers. Other suitable thermoplastic elastomer blends include butyl-polyethylene (e.g. in a ratio
10 ranging between about 2:3 and about 3:2) and butyl-polypropylene.

Typically, the sealing ring and/or the second sealing ring additionally comprises lubricant material. Suitably, the sealing ring and/or the second sealing ring comprises up to 30%, preferably from 5 to 20% lubricant material.

15 In addition, the stem may also comprise lubricant material. Suitably, the valve stem comprises up to 30%, preferably from 5 to 20% lubricant material.

20 The term 'lubricant' herein means any material which reduces friction between the valve stem and seal. Suitable lubricants include silicone oil or a fluorocarbon polymer such as polytetrafluoroethane (PTFE) or fluoroethylene propylene (FEP).

Lubricant can be applied to the stem, sealing ring or a second sealing ring by any suitable process including coating and impregnation, such as by injection or a tamponage process.
25

Optionally a moisture absorbing means may be incorporated within the dispenser as a component thereof. Alternatively, the moisture absorbing means may be a separate component of the formulation contained within the dispenser.

30 The moisture absorbing means may comprise a component or accessory for use with a canister or valve including a desiccant such as a molecular sieve, silica gel and/or a component or accessory that is made from a plastics material which is a natural desiccant, such as a polyamide, for example nylon, or may be moulded from other

plastics material such as acetal or PBT. Alternatively, or in addition, the moisture absorbing means may comprise an internal lining or coating. In one embodiment, the moisture absorbing means may be incorporated into a treatment or coating for canisters and/or valves for preventing drug deposition and/or maintaining dose uniformity.

5

Other vapour or moisture absorbing materials include desiccants made from inorganic materials such as zeolites and aluminas. Such inorganic materials have high water absorption capacities and favourable water absorption isotherm shapes. The water absorption capacity of such materials typically varies from 20 to 50 weight percent.

10

Other exemplary moisture absorbing materials include, but are not limited to, alumina, bauxite, anhydrous, calcium sulphate, water-absorbing clay, activated bentonite clay, a molecular sieve, or other like materials.

15

In conjunction with the desiccant an additional compound may be added to act as a conduit/channelling agent to increase/optimize the efficiency of the moisture absorption properties. Such materials may include compounds such as polyethylene glycols.

20

Preferably, the means for absorbing moisture reduces the rise in moisture content over time, and/or the decrease in Fine Particulate Mass over time by between 20 and 100%, for example, 40 to 70%, e.g. 45 to 55%. Typically, the component or accessory takes the form of a cap and/or a seal and/or a lining.

25

Furthermore desiccant material may be included in the packaging material for the device.

30

The desiccant should be present in an amount sufficient to absorb any increases in moisture around the valve area of the MDI and thus alleviate or substantially prevent moisture increases inside the canister.

Typically, 100µg to 5g, for example, 1mg to 1g, e.g. 100mg to 500mg, such as about 100mg to 250mg of desiccant may be included.

Canisters according to the invention may be filled with pharmaceutical formulations suitable for administration to patients e.g. those suffering from respiratory disorders such as asthma and COPD. Suitable formulations generally comprise a liquefied propellant gas such as a hydrofluoroalkane e.g. HFA134a or HFA227 and one or more drug substances.

Thus provided is a canister according to the invention containing a formulation comprising medicament and hydrofluoroalkane propellant. Preferably the propellant is selected from 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoro-n-propane and mixtures thereof, especially 1,1,1,2-tetrafluoroethane.

Preferably the medicament will be in particulate form of a mass median diameter so as to permit inhalation into the bronchial airways i.e. generally less than 100 microns e.g. between around 1 and 10 microns especially 1-5 microns. Particle size reduction can be achieved e.g. by micronisation. Optionally the formulation may contain a dispersing agent and/or a co-solvent such as a C₂₋₆ aliphatic alcohol (e.g. ethanol) or a polyol (e.g. propylene glycol or polyethyleneglycol), especially ethanol. A suitable amount of dispersing agent would be around 0.001-50%, e.g. 0.05-5% by weight of drug. A suitable amount of co-solvent would be around 0.005-15% e.g. 0.1-5% by weight of formulation. When conventional dispersing agents such as lecithin, sorbitan trioleate and oleic acid are employed then ethanol will generally be employed as well. Alternatively the drug may be dissolved in the liquefied propellant gas, generally by use of a co-solvent such as a C₂₋₆ aliphatic alcohol (e.g. ethanol) or a polyol (e.g. propylene glycol or polyethyleneglycol), especially ethanol. Certain preferred suspension formulations are free of all excipients besides the propellant and the particulate medicament. Such preferred formulations consist only of particulate medicament and propellant.

Example medicaments may thus be selected from, for example, analgesics, e.g. codeine, dihydromorphine, ergotamine, fentanyl or morphine; anginal preparations, e.g. diltiazem; antiallergics, e.g. cromoglycate (e.g. as the sodium salt), ketotifen or nedocromil (e.g. as the sodium salt); anti-infectives e.g. cephalosporins, penicillins, streptomycin, sulphonamides, tetracyclines and pentamidine; antihistamines, e.g. methapyrilene; anti-inflammatories, e.g. beclomethasone (e.g. as the dipropionate

ester), fluticasone (e.g. as the propionate ester), flunisolide, budesonide, rofleponide, mometasone e.g. as the furoate ester), ciclesonide, triamcinolone (e.g. as the acetonide) or 6 α , 9 α -difluoro-11 β -hydroxy-16 α -methyl-3-oxo-17 α -propionyloxy-androsta-1,4-diene-17 β -carbothioic acid S-(2-oxo-tetrahydro-furan-3-yl) ester; antitussives, e.g., noscapine; bronchodilators, e.g. albuterol (e.g. as free base or sulphate), salmeterol (e.g. as xinafoate), ephedrine, adrenaline, fenoterol (e.g. as hydrobromide), formoterol (e.g. as fumarate), isoprenaline, metaproterenol, phenylephrine, phenylpropanolamine, pirbuterol (e.g. as acetate), reproterol (e.g. as hydrochloride), rimiterol, terbutaline (e.g. as sulphate), isoetharine, tulobuterol or 4-hydroxy-7-[2-[[[3-(2-phenylethoxy)propyl]sulfonyl]ethyl]amino]ethyl-2(3H)-benzothiazolone, diuretics, e.g. amiloride; anticholinergics, e.g. ipratropium (e.g. as bromide), tiotropium, atropine or oxitropium; hormones, e.g. cortisone, hydrocortisone or prednisolone; xanthines, e.g. aminophylline, choline theophyllinate, lysine theophyllinate or theophylline. It will be clear to a person skilled in the art that, where appropriate, the medicaments may be used in the form of salts, (e.g. as alkali metal or amine salts or as acid addition salts) or as esters (e.g. lower alkyl esters) or as solvates (e.g. hydrates) to optimise the activity and/or stability of the medicament and/or to minimise the solubility of the medicament in the propellant.

Preferred medicaments are selected from albuterol, salmeterol, fluticasone propionate and beclomethasone dipropionate and salts or solvates thereof, e.g. the sulphate of albuterol and the xinafoate of salmeterol and mixtures thereof.

Medicaments can also be delivered in combinations. Preferred formulations containing combinations of active ingredients contain salbutamol (e.g. as the free base or the sulphate salt) or salmeterol (e.g. as the xinafoate salt) or formoterol (e.g. as the fumarate salt) in combination with an anti-inflammatory steroid such as a beclomethasone ester (e.g. the dipropionate) or a fluticasone ester (e.g. the propionate) or budesonide. A particularly preferred combination is a combination of fluticasone propionate and salmeterol, or a salt thereof (particularly the xinafoate salt). A further combination of particular interest is budesonide and formoterol (e.g. as the fumarate salt).

The final drug concentration in the formulation is preferably between 0.005-10% w/w more preferably 0.005-5% e.g. 0.01-1% w/w by weight of formulation. Preferably the concentration will be such as to deliver a therapeutic dose of the medicament in one or two actuations. Example therapeutic doses are 25, 50, 125 or 250µg per actuation of
5 fluticasone propionate taken twice per day, 25µg per actuation of salmeterol (as xinafoate) taken twice per day, 100µg of salbutamol (e.g. as free base or sulphate) taken twice as needed and 50 or 250 µg per actuation of beclomethasone dipropionate taken twice two or three times per day.

10 The invention is illustrated by reference to the following examples.

Example 1

A laminate comprising two sheets of aluminium and a sheet of stainless steel each of thickness 0.2mm is formed using a pressure sensitive adhesive, heating and pressure
15 lamination rollers, so as to form a sandwich of a steel layer between two aluminium layers. The laminate is deep drawn into the shape of a conventional MDI canister (approximate dimensions: diameter 22.1-22.2 mm, height 33.4-61.15mm; wall thickness 0.3-0.75 mm).

20 Example 2

The canister of Example 1 is spray coated on its internal surface with a blend of PTFE and PES and cured at between 350 to 400°C for approximately 10 minutes.

Example 3

25 The canister of Example 1 is spray coated on its internal surface with FEP and cured 350 to 400°C for approximately 10 minutes.

Example 4

30 The canisters of Examples 1, 2 and 3 may be fitted with a metering valve (Valois DF60) and filled through the valve with a suspension of fluticasone propionate in liquefied HFA134a.

Example 5

The canisters of Examples 1, 2 and 3 may be fitted with a metering valve (Valois DF60) and filled through the valve with a suspension of salmeterol xinafoate in liquefied HFA134a.

5 Example 6

The canisters of Examples 1, 2 and 3 may be fitted with a metering valve (Valois DF60) and filled through the valve with a suspension of salbutamol sulphate in liquefied HFA134a.

10 Example 7

The canisters of Examples 1, 2 and 3 may be fitted with a metering valve (Valois DF60) and filled through the valve with a suspension of fluticasone propionate and salmeterol xinafoate in liquefied HFA134a.

Claims

1. A canister suitable for use in metered dose inhalers and fitted with a metering valve characterised in that its walls are formed of a laminate comprising a first layer which is composed of a metal and a second layer which is composed of a strengthening material.

2. A canister as claimed in claim 1 wherein the second layer of strengthening material is a reinforced plastic selected from: polyester, polypropylene, acetonitrile-styrene copolymer, high-impact styrene, nylon or polyacetal and the first metal layer is composed of a material selected from aluminium or steel and characterised in that the first metal layer forms the internal surface of the canister and is optionally coated with one or more coating layers and an adhesive layer is optionally used between the reinforced plastic layer and the first metal layer.

3. A canister as claimed in claim 1 wherein the second layer of strengthening material is a reinforced plastic selected from: polyester, polypropylene, acetonitrile-styrene copolymer, high-impact styrene, nylon or polyacetal and is optionally coated with one or more coating layers and the first metal layer is composed of a material selected from aluminium or steel and characterised in that the first metal layer forms the external surface of the canister and is optionally coated with one or more coating layers and an adhesive layer is optionally used between the reinforced plastic layer and the first metal layer.

4. A canister according to claim 1 characterised in that its walls are formed of a laminate wherein the laminate comprises a first metal layer of material forming the external surface of the canister selected from the list of metals consisting of: aluminium, brass, copper, chromium, iron, tin and steel, optionally coated with one or more coating layers, and a second layer of material selected from the list of strengthening materials consisting of aluminium, brass, copper, chromium, chromium oxide, iron, tin and steel, optionally coated with one or more coating layers.

5. A canister according to claim 1 characterised in that its walls are formed of a laminate wherein the laminate comprises a first metal layer of material forming the internal surface of the canister selected from the list of metals consisting of: aluminium, brass, copper, chromium, iron, tin and steel, optionally coated with one or more coating layers and a second layer of material selected from the list of strengthening materials consisting of aluminium, brass, copper, chromium, chromium oxide, iron, tin and steel, optionally coated with one or more coating layers.

6. A canister according to claims 1 to 5 wherein the first metal layer is aluminium or stainless steel.
7. A canister according to claim 6 wherein the first metal layer is aluminium.
- 5 8. A canister according to any one of claims 1 to 7 wherein the canister is formed from a laminate comprising a layer of steel sandwiched between two layers of aluminium (i.e. is a laminate of one layer of steel and two layers of aluminium), and optionally the internal and/or external aluminium walls are provided with one or more coating layers.
- 10 9. A canister according to any one of claims 1 to 8 containing a formulation comprising medicament and hydrofluoroalkane propellant.
10. A canister according to claim 9 wherein the propellant is selected from 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoro-n-propane and mixtures thereof.
11. A canister according to claim 10 wherein the propellant is 1,1,1,2-tetrafluoroethane.
- 15 12. A canister according to any one of claims 9 to 11 wherein the formulation is a suspension formulation free of all excipients besides propellant and the particulate medicament.
- 20 13. A canister according to any one of claims 1 to 12 wherein the medicament is selected from fluticasone propionate, beclomethasone dipropionate, salmeterol, albuterol and salts or solvates thereof and mixtures thereof.

PCT GB 02 01088

K S.